https://www.adnkronos.com/Archivio/salute/farmaceutica/leucemia-linfatica-cronica-ok-da-aifa-a-rimborsabilita-in-italia-di-pirtobrutinib_4mKMAEXZOLKRoXhsNhvbbT
Leucemia linfatica cronica, ok da Aifa a rimborsabilità in Italia di pirtobrutinib
La nuova opzione terapeutica di Lilly è disponibile in fascia H con monitoraggio tramite Registro Aifa, a seguito della pubblicazione in Gu dello scorso marzo
in italialeucemialinfaticacronicaaifa
https://medicaex.com/prnewswire/jaypirca-pirtobrutinib-approved-in-china-for-a-new-indication-in-chronic-lymphocytic-leukemia-cll-small-lymphocytic-lymphoma-sll-across-all-lines-of-therapy/
Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia...
Sep 29, 2026 - SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company
chronic lymphocytic leukemiain chinapirtobrutinibapprovednew
https://www.pharmaceutical-technology.com/data-insights/pirtobrutinib-eli-lilly-and-co-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/
Pirtobrutinib by Eli Lilly and Co for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of...
Jan 20, 2025 - Pirtobrutinib is under clinical development by Eli Lilly and Co and currently in Phase III for Relapsed Chronic Lymphocytic Leukemia (CLL).
chronic lymphocytic leukemiaeli lillypirtobrutinibrelapsedcll